Market Cap 2.91B
Revenue (ttm) 218.71M
Net Income (ttm) -113.70M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -51.99%
Debt to Equity Ratio 0.00
Volume 812,900
Avg Vol 883,244
Day's Range N/A - N/A
Shares Out 87.81M
Stochastic %K 31%
Beta 0.09
Analysts Strong Sell
Price Target $50.06

Company Profile

IDEAYA Biosciences, Inc., a precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer driven by GNAQ/11 mutations, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant,...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 443 6209
Address:
5000 Shoreline Court, Suite 300, South San Francisco, United States
Davy_Stockett
Davy_Stockett Mar. 15 at 4:27 AM
$IDYA I’ll bite. Readout looks very promising. What looks more promising is the confluence of top tier institutions.
0 · Reply
CH_Expat
CH_Expat Mar. 12 at 9:42 AM
$IDYA My guess: a HR probably under 0.5, maybe even 0.4 or lower and mPFS not reached in the treatment arm. The math lines up: With 130 events triggered early, control must've flopped fast (like 2.8–3 months, as historical), so most events are theirs. Treatment stays strong – patients still progression-free, curve way to the right, median never crosses.
1 · Reply
Quantumup
Quantumup Mar. 9 at 1:58 PM
Truist reiterated $IDYA Buy/$60 $RVMD $TNGX IMRX $BMY $AMGN Here's what Truist said in its note: https://x.com/Quantumup1/status/2031005706770350568?s=20
0 · Reply
StockNews_Live
StockNews_Live Mar. 9 at 10:00 AM
$IDYA IDEAYA Biosciences announced the enrollment of the first patient in its Phase 1 clinical trial evaluating IDE892, an investigational MTA-cooperative PRMT5 inhibitor for patients with MTAP-deleted soli…
0 · Reply
CH_Expat
CH_Expat Mar. 6 at 3:16 PM
$IDYA No steam behind it. Little volume. They want to scare us a bit before the readout.
1 · Reply
CDMO
CDMO Mar. 5 at 8:33 PM
$IDYA another 100 added
0 · Reply
HeraklesTrading
HeraklesTrading Mar. 4 at 8:11 PM
$IDYA solid investment here for me !! $CAPR very good chance of triple down and more until later summer !!
1 · Reply
CH_Expat
CH_Expat Mar. 4 at 6:40 PM
$IDYA If 40 before data,I will reduce my position by 1/4. If we go back to 30 before data, I will add another 2000 shares. In this range, just hold.
1 · Reply
Social_Idiot
Social_Idiot Mar. 4 at 3:31 PM
$IDYA It's trying!
0 · Reply
NorthStarStats
NorthStarStats Mar. 4 at 10:52 AM
Market is full of failed breakout and rug pulls. Be careful. From the scanner: $IDYA Score: 98.00, $TGT Score: 73.00, $DAY Score: 70.00, $VTYX Score: 70, $RTX Score: 68.00
2 · Reply
Latest News on IDYA
Ideaya Biosciences: Moving Into ADCs For Solid Tumors

Aug 5, 2025, 8:43 AM EDT - 7 months ago

Ideaya Biosciences: Moving Into ADCs For Solid Tumors


Davy_Stockett
Davy_Stockett Mar. 15 at 4:27 AM
$IDYA I’ll bite. Readout looks very promising. What looks more promising is the confluence of top tier institutions.
0 · Reply
CH_Expat
CH_Expat Mar. 12 at 9:42 AM
$IDYA My guess: a HR probably under 0.5, maybe even 0.4 or lower and mPFS not reached in the treatment arm. The math lines up: With 130 events triggered early, control must've flopped fast (like 2.8–3 months, as historical), so most events are theirs. Treatment stays strong – patients still progression-free, curve way to the right, median never crosses.
1 · Reply
Quantumup
Quantumup Mar. 9 at 1:58 PM
Truist reiterated $IDYA Buy/$60 $RVMD $TNGX IMRX $BMY $AMGN Here's what Truist said in its note: https://x.com/Quantumup1/status/2031005706770350568?s=20
0 · Reply
StockNews_Live
StockNews_Live Mar. 9 at 10:00 AM
$IDYA IDEAYA Biosciences announced the enrollment of the first patient in its Phase 1 clinical trial evaluating IDE892, an investigational MTA-cooperative PRMT5 inhibitor for patients with MTAP-deleted soli…
0 · Reply
CH_Expat
CH_Expat Mar. 6 at 3:16 PM
$IDYA No steam behind it. Little volume. They want to scare us a bit before the readout.
1 · Reply
CDMO
CDMO Mar. 5 at 8:33 PM
$IDYA another 100 added
0 · Reply
HeraklesTrading
HeraklesTrading Mar. 4 at 8:11 PM
$IDYA solid investment here for me !! $CAPR very good chance of triple down and more until later summer !!
1 · Reply
CH_Expat
CH_Expat Mar. 4 at 6:40 PM
$IDYA If 40 before data,I will reduce my position by 1/4. If we go back to 30 before data, I will add another 2000 shares. In this range, just hold.
1 · Reply
Social_Idiot
Social_Idiot Mar. 4 at 3:31 PM
$IDYA It's trying!
0 · Reply
NorthStarStats
NorthStarStats Mar. 4 at 10:52 AM
Market is full of failed breakout and rug pulls. Be careful. From the scanner: $IDYA Score: 98.00, $TGT Score: 73.00, $DAY Score: 70.00, $VTYX Score: 70, $RTX Score: 68.00
2 · Reply
CDMO
CDMO Mar. 3 at 3:05 PM
$IDYA tempted to add
1 · Reply
CH_Expat
CH_Expat Mar. 3 at 2:35 PM
$IDYA Intense.
0 · Reply
CH_Expat
CH_Expat Mar. 3 at 8:40 AM
$IDYA Directory Jeffrey Stein bought the small amount of 50.000 shares for around 32.50 USD on March 2nd. Not exactly bearish.
2 · Reply
dR_HumanEvolution
dR_HumanEvolution Mar. 2 at 8:54 PM
0 · Reply
CH_Expat
CH_Expat Mar. 2 at 7:30 PM
$IDYA Really strong on a day like today. Hard to play this one correctly. Normally one should hold this for a very long time considering the other great assets apart from Daro, but apart from very few examples like VRNA, it was mostly the right decision to take the double and buy back lower. Very interesting weeks and months ahead.
0 · Reply
StockNews_Live
StockNews_Live Feb. 28 at 12:00 AM
$IDYA IDEAYA Biosciences has dosed the first patient in its Phase 1 trial of IDE034, a B7H3/PTK7 bispecific TOP1 ADC. The trial will evaluate the safety, tolerability, and PK of IDE034 as a monotherapy and …
0 · Reply
CH_Expat
CH_Expat Feb. 27 at 7:13 PM
$IDYA and $KURA are still my only substantial positions. Not going to force it when it is not there. At the moment, there is no SWTX for 20 or $SNDX at 10 to fish right now...
1 · Reply
CH_Expat
CH_Expat Feb. 25 at 6:04 PM
$IDYA Guys, you should indeed check Jerome Leonard on X. It is worth it. The status update yesterday at Evercore brought some important news ans insights. Too complex to put it together here.
1 · Reply
briefingcom
briefingcom Feb. 25 at 1:10 PM
$IDYA: IDEAYA Biosciences announced that the first patient has been enrolled in its Phase 1 dose escalation/expansion trial evaluating IDE034, an investigational PTK7/B7H3 bispecific TOP1 ADC https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20260225060155IDYA&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page
0 · Reply
Popal
Popal Feb. 24 at 3:03 PM
0 · Reply
Daddy044
Daddy044 Feb. 23 at 6:54 PM
$IDYA New report Strong https://docs.google.com/document/d/1FwCvxNu18rizGwL6BoGFQrqsUfhhS2fMO_zPZRjmLnU/edit?usp=sharing
0 · Reply
CH_Expat
CH_Expat Feb. 23 at 5:24 PM
$IDYA "The data will speak for itself " CEO a minute ago in the Status Update
1 · Reply